Skip to main content
SpringerLink
Log in

Les thérapeutiques ciblées ou le traitement des mécanismes moléculaires de la progression tumorale

  • Chapter
Les cancers ovariens

Part of the book series: Abord clinique ((ONCOLPRAT))

  • 324 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Savage DG, Antman KH (2002) Imatinib mesylate—a new oral targeted therapy. N Engl J Med 346: 683–93

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1084–6

    Google Scholar 

  3. Druker BJ, Sawyers CL, Kantarjian H et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–42

    CAS  PubMed  Google Scholar 

  4. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastro-intestinal stromal tumor. N Eng J Med 344: 1052–6

    CAS  Google Scholar 

  5. Ray-Coquard I, Le Cesne A, Blay JY (2001) [STI571 and gastro-intestinal stromal tumors]. Bull Cancer 88: 661–2

    CAS  PubMed  Google Scholar 

  6. Van Oosterom A, Judson I, Verwej J et al. (2002) Update of the Imatimib (STI 571, Imatinib) phase I in gastro-intestinal stromal tumors. Proc Am Soc Clin Oncol 21 (abstract 327)

    Google Scholar 

  7. Van Oosterom A, Judson I, Verwej J et al. (2001) Safety and efficacy of Imatimib (STI-571) in metastatic gastro-intestinal stromal tumors: a phase I study. Lancet 358: 1421–3

    PubMed  Google Scholar 

  8. Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastro-intestinal stromal tumors. N Engl J Med 347: 472–80

    Article  CAS  PubMed  Google Scholar 

  9. Verweij J, van Oosterom AT, Blay JY et al. (2003) Imatinib (Gleevec) an active agent for gastro-intestinal stromal tumors (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PDGF-R ex-pression, results of EORTC phase II studies. Eur J Cancer 39(14): 2006–11

    Article  CAS  PubMed  Google Scholar 

  10. Berman J, O’Leary TJ (2001) Gastro-intestinal stromal tumor workshop. Hum Pathol 32: 578–82

    Article  CAS  PubMed  Google Scholar 

  11. Pidhorecky I, Cheney RT, Kraybill WG (2000) Gastro-intestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7: 705–12

    CAS  PubMed  Google Scholar 

  12. Miettinen M, Sarlomo-Rikala M, Lasota J (1999) Gastro-intestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 30: 1213–20

    CAS  PubMed  Google Scholar 

  13. Nishida T, Hirota S (2000) Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 15: 1293–301

    CAS  PubMed  Google Scholar 

  14. Longley BJ, Reguera MJ, Ma Y (2001) Classes of c-kit activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 25: 571–6

    Article  CAS  PubMed  Google Scholar 

  15. Linnekin D (1999) Early signaling pathways activated by c-kit in hematopoietic cells. Int J Bioch Cell Biol 31: 1053–74

    CAS  Google Scholar 

  16. Huizinga JD, Thuneberg L, Kluppel M et al. (1995) W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373: 347–9

    CAS  PubMed  Google Scholar 

  17. Vliagoftis H, Worobec AS, Metcalf DD (1997) The proto-oncogene c-kit and c-kit ligand in human disease. J Alleg Clin Immunol 100: 435–40

    CAS  Google Scholar 

  18. Andersson J, Sjogren H, Meis-Kindblom et al. (2002) The complexicity of KIT gene mutations and chromosome re-arrangements and their clinical correlation in gastro-intestinal stromal (pacemaker cell) tumors. Amer J of Pathol 160

    Google Scholar 

  19. Heinrich MC, Corless CL, Blanke C et al. (2002) KIT mutational status predict clinical response to STI-571 in patients with metastatic gastro-intestinal stromal tumors. Proc. Am Soc Clin Soc 21 (abstract 6)

    Google Scholar 

  20. Maeyama H, Hidaka E, Ota H et al. (2001) Familial gastro-intestinal stromal tumor with hyperg-mentation: association with a germline mutation of the c-kit gene. Gastro-enterology 120: 210–5

    CAS  Google Scholar 

  21. Franquemont DW (1995) Differentiation and risk assessment of gastro-intestinal stromal tumors. Am J Clin Pathol 103: 41–7

    CAS  PubMed  Google Scholar 

  22. Cooper PN, Quirque P, Hardy GJ et al. (1992) A flow, cytometric, clinical and histological study of stromal neoplasms of the gastro-intestinal tract. Am J Surg Pathol 16: 163–70

    CAS  PubMed  Google Scholar 

  23. Cunnigham RE, Federspiel BH, McCarthy WF et al. (1993) Predicting prognosis of gastrointestinal stromal smooth muscle tumors: Role of clinical and histologic evaluation, flow cyto-metry and image cytometry. Am J Surg Pathol 17: 588–94

    Google Scholar 

  24. Taniguchi M, Nishida T, Hirota S et al. (1999) Effect of c-kit mutation on prognosis of gastro-intestinal stromal tumors. Cancer Res 59: 4297–300

    CAS  PubMed  Google Scholar 

  25. Lasota J, Jazinski M, Sarlomo-Rikala M et al. (1999) Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastro-intestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154: 53–60

    CAS  PubMed  Google Scholar 

  26. Seidal T, Edvardsson H (1999) Expression of c-kit and Ki 67 provides information about the possible cell of origin and clinical course of gastro-intestinal stromal tumours. Histopathology 34: 416–24

    Article  CAS  PubMed  Google Scholar 

  27. Berman J, O’Leary T (2001) Gastro-intestinal stromal tumors workshop. Human Pathol 32: 578–82

    CAS  Google Scholar 

  28. Singer S, Rubin BP, Lux ML et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastro-intestinal stromal tumors. J Clin Oncol 15; 20(18): 3898–905

    CAS  Google Scholar 

  29. Heinrich MC, Corless CL, Duensing A et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607): 708–10. Epub 2003 Jan 09

    Article  CAS  PubMed  Google Scholar 

  30. Corless C, Fletcher JA, Heinrich MC (2004) Biology of gastro-intestinal stromal tumors. J Clin Oncol 22: 3813–25

    Article  CAS  PubMed  Google Scholar 

  31. Verweij J, Casali P, Zalcberg J et al. (2004) Improved progression free survival in gastro-intestinal stromal tumors with high dose Imatinib. Results of a randomized phase III study of the EORTC, ISG and AGITG. Lancet 364: 1127–34

    Article  CAS  PubMed  Google Scholar 

  32. Blay JY, Bonvalot S, Casali P et al. (2005) Consensus Meeting for the management of Gastro-Intestinal Stromal Tumors. Report of the GIST consensus conference of March 20–21st, 2004 under the auspices of ESMO. Ann Oncol 16(4): 566–78

    Article  PubMed  Google Scholar 

  33. Debiec-Rychter M, Dumez H, Judson I et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastro-intestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689–95

    Article  CAS  PubMed  Google Scholar 

  34. Demetri GD, Desai J, Fletcher JA et al. (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastro-intestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 23, 195 (abstract 3001)

    Google Scholar 

  35. Apperley J, Garembas M, Melo JV et al. (2002) Response to imatinib mesylate in patients with chronic myelomonocytic leukemia with re-arrangements or platelet derived growth factor receptor beta. New Engl J Med 347: 481–7

    Article  CAS  PubMed  Google Scholar 

  36. Simon MP, Pedeutour F, Sirvent N et al. (1997) Deregulation of the latelet derived growth factor gene via fusion with col1a1 in dermatofibrosarcoma protuberans and giant cell fibroblastoma. Nat Genet 15: 95–8

    Article  CAS  PubMed  Google Scholar 

  37. Rubin BP, Schuetze SM, Eary JF et al. (2002) Molecular targeting of PDGF B by imatinib mesylate in a patient with metasatic dermatofibro-sarcoma protuberans. J Clin Oncol 20: 3586–91

    Article  CAS  PubMed  Google Scholar 

  38. Maki RG, Awan RA, Dixon RH et al. (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100: 623–6

    Article  CAS  PubMed  Google Scholar 

  39. Pardanani A, Ketterling RP, Brockman SR et al. (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood

    Google Scholar 

  40. JS, Fletcher JA, Linette GP, Stec J et al. (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4): 307–254

    PubMed  Google Scholar 

  41. Spigel DR, Burstein HJ (2003) Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 4(5): 329–37

    CAS  PubMed  Google Scholar 

  42. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal anti-body against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  CAS  PubMed  Google Scholar 

  43. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2: 727–39

    Article  CAS  PubMed  Google Scholar 

  44. Yang JC, Haworth L, Sherry RM et al. (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–34

    Article  CAS  PubMed  Google Scholar 

  45. Negrier S, Perol D, Menetrier-Caux C et al. (2004) Groupe français d’Immunotherapie. Interleukin-6, inter-leukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6—from the Groupe Francais d’Immunotherapie. J Clin Oncol Jun 15; 22(12): 2371–8

    CAS  Google Scholar 

  46. Hurwitz H, Fehrenbacher L (2004) Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3; 350(23): 2335–42

    Article  CAS  PubMed  Google Scholar 

  47. Motzer RJ, Rini I, Michaelson MD et al. (2004) SU011248, a novel tyrosine kinase inhibitor shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. Proc ASCO 23: 381 (abstract 4500)

    Google Scholar 

  48. Ratain MJ, Flaherty KT, Stadler WM et al. (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. Proc ASCO 23: 381 (abstract 4501)

    Google Scholar 

  49. Sridhar SS, Seymour L, Shepherd FA (2003) Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4: 397–406

    Article  CAS  PubMed  Google Scholar 

  50. Giaccone G (2004) The role of gefitinib in lung cancer treatment. Clin Cancer Res Jun 15; 10(12 Pt 2): 4233s–4237s

    CAS  Google Scholar 

  51. Birnbaum A, Ready N (2005) Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol. 2005 Jan; 6(1): 75–81

    Google Scholar 

  52. Perez-Soler R, Chachoua A, Hammond LA et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16): 3238

    Article  CAS  PubMed  Google Scholar 

  53. Cappuzzo F, Gregorc V, Rossi E et al. (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21: 2658–63

    Article  CAS  PubMed  Google Scholar 

  54. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350(21): 2129–39

    Article  CAS  PubMed  Google Scholar 

  55. Paez JG, Janne PA, Lee JC et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 4; 304(5676): 1497–500

    Article  CAS  PubMed  Google Scholar 

  56. Sordella R, Bell DW, Haber DA et al. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687): 1163–7

    Article  CAS  PubMed  Google Scholar 

  57. Pao W, Miller V, Zakowski M et al. (2004) EGF receptor gene mutations are common in lung cancers from “ never smokers ” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 Sep 7; 101(36): 13306–11

    Article  CAS  PubMed  Google Scholar 

  58. Stephens P, Hunter C, Bignell G et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431(7008): 525–6

    Article  CAS  PubMed  Google Scholar 

  59. Hainsworth JD, Sosman JA, Spigel DR et al. (2004) Phase II trial or bevacizumab and erlotinib in patients ith metastatic renal cell carcinoma. Proc ASCO 23: 381 (abstract 4502)

    Google Scholar 

  60. Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). New Engl J Med 351: 337–45

    Article  CAS  PubMed  Google Scholar 

  61. Robert F, Ezekiel MP, Spencer SA et al. (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234–43

    CAS  PubMed  Google Scholar 

  62. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14: 520–35

    CAS  PubMed  Google Scholar 

  63. Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30(1 Suppl 2): 3–8

    CAS  PubMed  Google Scholar 

Download references

Authors
  1. J.-Y. Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Fayette
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Blay, JY., Fayette, J., Ray-Coquard, I. (2006). Les thérapeutiques ciblées ou le traitement des mécanismes moléculaires de la progression tumorale. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_38

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_38

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation